Browse the evidence

A dual/poly-GPCR agonism strategy has emerged as an alternative approach to the traditional mono-GPCR concept.

Practitioners may consider exploring dual/poly-GPCR strategies in obesity treatment.

Drug-related adverse events (AEs) were reported by 39.0% of participants in parts 1 + 2 and 30.6% in part 3.

Practitioners should be aware of the incidence of AEs when considering BI 1820237 for treatment.

Adverse events from SGLT-2 inhibitors and GLP-1RAs are primarily mild to moderate and tend to subside with treatment adjustment.

Practitioners should monitor for mild to moderate gastrointestinal side effects when prescribing these medications.

Caution is advised when initiating GLP-1 agonist therapy in HIV patients taking protease inhibitors.

Healthcare providers should monitor HIV patients on protease inhibitors closely when starting GLP-1 agonists.

LA-induced mitochondrial perturbations are linked with gut dysbiosis.

Addressing mitochondrial health may also improve gut microbiome balance.

Sarcopenia is associated with 1.60 to 5.80 greater odds of activities of daily living (ADL) disability.

Practitioners should consider sarcopenia as a significant risk factor for ADL disability in older adults.

Agreement between methods of operationalizing grip strength is modest.

Practitioners should be cautious about the variability in grip strength measurements when assessing sarcopenia.

The LLHR group demonstrated a trivial difference in fat free mass (FFM) favoring LLHR vs ST of 0.27 kg (95 % CI (-0.87, 1.42)).

Lighter load training may not significantly increase fat-free mass compared to traditional training.

Gastrointestinal side effects from tirzepatide are common but mild to moderate, with less than 5% treatment discontinuation.

Practitioners should be aware of potential mild gastrointestinal side effects when prescribing tirzepatide.

The distribution of protein intake (balanced vs unbalanced) did not influence myofibrillar protein synthesis rates.

The timing and distribution of protein intake may not be critical for maximizing muscle protein synthesis in young adults.

Sarcopenic diabetes is recognized as a distinct clinical condition that requires more awareness and research.

There is a need for increased focus on sarcopenic diabetes in clinical practice and research.

Serum or adipose L-aspartate levels were found to be negatively correlated with the severity of obesity in both humans and mice.

Monitoring L-aspartate levels could be relevant in assessing obesity risk.

Myonuclear accretion and satellite cell (SC) content did not significantly differ between the MIS and COL groups after 10 weeks of RET.

Both types of supplementation may not significantly affect myonuclear and satellite cell content during resistance training.

GLP-1RAs can cause gastrointestinal adverse events such as nausea, vomiting, and diarrhea.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing GLP-1RAs.

Significant weight loss induced by caloric restriction and metabolic and bariatric surgery (MBS) results in high turnover bone loss.

Practitioners should be aware that significant weight loss from caloric restriction and MBS can lead to increased bone loss.

Weight loss after metabolic and bariatric surgery (MBS) is associated with a substantial deterioration in bone microarchitecture and strength, increasing fracture risk.

Clinicians should monitor bone health closely in patients undergoing MBS due to increased fracture risk.

Significant weight loss induced by GLP-1 receptor agonists (GLP-1Ra) may result in accelerated bone turnover and bone loss.

Healthcare providers should consider the impact of GLP-1Ra on bone health when prescribing these medications.

Dulaglutide is associated with a significantly higher risk of overall hematologic malignancy (OR = 2.18, 95%CI = 1.14-4.19).

Clinicians should be cautious when prescribing dulaglutide due to its association with increased hematologic malignancy risk.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate notable cardiovascular benefits beyond glucose regulation in patients with coronary artery disease (CAD).

Practitioners should consider SGLT2i and GLP-1 RAs for cardiovascular protection in CAD patients.

GLP-1 receptor agonist patients demonstrated higher overall complication rates (20%) compared to controls (10%), though this was not statistically significant (p=0.47).

Clinicians should be aware of the potential for higher complication rates in patients using GLP-1 receptor agonists.

GLP-1 medicines may contribute to decreased cancer incidence.

Consider the potential cancer risk reduction when prescribing GLP-1 medicines.

Lower mitochondrial oxidative phosphorylation (OXPHOS) capacity and inactivity contribute to lower insulin sensitivity in individuals with Friedreich's ataxia (FRDA).

Improving mitochondrial function and physical activity may enhance insulin sensitivity in FRDA patients.

Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence.

Clinicians should be aware of the potential for gastrointestinal side effects, particularly with Semaglutide.

GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy.

Clinicians should monitor patients on GLP-1 RAs for signs of gastroparesis and intussusception.